EUVIMED · CrossrefJournal
Generics and Biosimilars Initiative Journal
ISSN 2033-6403 · Pro Pharma Communications International
Latest articles
Do pricing and usage-enhancing policies differ between biosimilars and generics? Findings from an international survey
ICH Q11: development and manufacture of drug substances–chemical and biotechnological/biological entities
Introduction to the GaBI Journal
Generic medicine pricing: on track in Europe?
Innovator companies should focus on innovations
A review of generic medicine pricing in Europe
Biologicals and biosimilars: a review of the science and its implications
A patient-centred paradigm for the biosimilars market
European payer initiatives to reduce prescribing costs through use of generics
A review of patient perspectives on generics substitution: what are the challenges for optimal drug use
Myths, questions, facts about generic drugs in the EU
Generic and therapeutic orphans
How matrix models can support generic medicine prescribing
Rhythm
What to look forward to in GaBI Journal, 2012, issue 2
Equal protection under the law: Children and the Best Pharmaceuticals for Children Act
Tighter EU rules on pharmacovigilance for biologicals
What lessons can be learned from the launch of generic clopidogrel?
Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach
Promoting access to biosimilars: a public−private partnership model for biosimilar development in underserved populations
Generic clopidogrel–the medicines agency’s perspective
The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries─an overview
Generics substitution in primary care: summary of the Dutch community pharmacies guidelines
Oncologists urged to embrace biosimilars to help control spiralling costs of cancer care
Readers' Comments
Terminology for biosimilars–a confusing minefield
Health professionals in the risk communication process on counterfeit medicines
Generics policies–a globally-relevant implementation challenge
Reference pricing systems in Europe: characteristics and consequences
The MEDICRIME Convention: criminalising the falsification of medicines and similar crimes
EUVIMED